Interviews

Jean-Jaques Kiladjian, MD, PhD, discusses how the results from the RESPONSE trial impact patients with polycythemia vera.

Kabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.

Toni K. Choueiri, MD, discusses the current role of immunotherapy in the treatment of patients with renal cell carcinoma.

Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.

Al B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.

Rajneesh Nath, MD, director, stem cell transplant and acute leukemia program, Banner MD Anderson Cancer Center, discusses the ongoing&nbsp;phase III SIERRA trial, which is evaluating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).<br /> &nbsp;

Viola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma

Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.

Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at Medstar Washington Hospital Center, discusses how surgical approaches have evolved in gynecologic cancers.

Leisha A. Emens, MD, PhD, professor of medicine at the UPMC Cancer Center, discusses how the data from the IMpassion130 trial have demonstrated benefit for immunotherapy in metastatic triple-negative breast cancer.

Jame Abraham, MD, discusses the results for the phase Ib study of trastuzumab emtansine with neratinib in patients with HER2-positive breast cancer.

Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab&nbsp; in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.

Peter Voorhees, MD, investigator, department of hematologic oncology &amp; blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.

Edward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).&nbsp;

Tanios Bekaii-Saab, MD, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.

<br /> Farhad Ravandi-Kashani, MD, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia.

Mark G. Kris, MD, discusses what is most important in treating patients with lung cancer today.

Ajai Chari, MD, discusses the biggest challenge in treating patients with multiple myeloma.

Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab plus lenalidomide or a physician&rsquo;s choice of bendamustine and rituximab plus CHOP or R-CHOP.

Laura Michaelis, MD, discusses how to select patients with either polycythemia vera or essential thrombocythemia for cytoreductive therapy.

Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.

Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma.&nbsp;

Lori J. Wirth, MD, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.

Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.

Jonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.

Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non&ndash;small cell lung cancer.

Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.&nbsp;